ArticleGastroenterology research and practice2012
Current concepts on gastric carcinoid tumors.
Article in Gastroenterology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.United European gastroenterology journal · 2020Pooled it
- A case of gastric neuroendocrine tumor with an unusual morphology.Clinical journal of gastroenterology · 2026Article
- Endoscopic submucosal dissection with deliberate muscularis propria exposure for curative resection of a large type 1 gastric neuroendocrine tumor: a case report.Frontiers in oncology · 2026Article
- Gastric neuroendocrine neoplasms: analysis of a cohort of patients followed at the Brazilian National Cancer Institute.Endocrine oncology (Bristol, England) · 2025Article
- Relation between WHO Classification and Location- and Functionality-Based Classifications of Neuroendocrine Neoplasms of the Digestive Tract.Neuroendocrinology · 2024Review
- Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors.Biomedicines · 2023Article
- GASTRIC NEUROENDOCRINE TUMOR: WHEN SURGICAL TREATMENT IS INDICATED?Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2023Article
- A rare case of an enterochromaffin-like neuroendocrine tumor associated with parietal cell dysfunction treated using endoscopic submucosal dissection.Clinical journal of gastroenterology · 2022Article
- Pathogenic ATM Variant-Harbouring Well-Differentiated Aggressive Type 1 Gastric Neuroendocrine Tumour with High-grade Features (G3 NET): a New Addition to the Clinical and Pathological Spectrum of Gastric Neuroendocrine Neoplasms.Endocrine pathology · 2021Article
- Gastric Neuroendocrine Tumor.Surgery journal (New York, N.Y.) · 2021Article
- Article
- Multiple endocrine neoplasia 1: a broad overview.Therapeutic advances in chronic disease · 2021Review
- The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK.BMC gastroenterology · 2020Article
- Autoimmune metaplastic atrophic gastritis and association with neuroendocrine tumors of the stomach.Clinical journal of gastroenterology · 2020Review
- A genetic origin for acid-base imbalance triggers the mitochondrial damage that explains the autoimmune response and drives to gastric neuroendocrine tumours.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2020Article
- Genomic dissection of gastrointestinal and lung neuroendocrine neoplasm.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- Gastric Neuroendocrine Tumors (Carcinoids).Current gastroenterology reports · 2019Review
- CDK5RAP3 inhibits angiogenesis in gastric neuroendocrine carcinoma by modulating AKT/HIF-1α/VEGFA signaling.Cancer cell international · 2019Article
- Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin AnalogJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
- Rare Entities of Histopathological Findings in 755 Sleeve Gastrectomy Cases: a Synopsis of Preoperative Endoscopy Findings and Histological Evaluation of the Specimen.Obesity surgery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric carcinoid tumors (GCs) are rare lesions representing less than 10% of carcinoid tumors and less than 1% of all stomach neoplasms. There are three distinct types of gastric carcinoids; type I includes the vast majority (70-85%) of these neoplasms that are closely linked to chronic atrophic gastritis. Type II which accounts for 5-10 %, is associated with Zollinger-Ellison syndrome and often occurs in the context of multiple endocrine neoplasia type 1. Type III, finally, represents 15-25% of gastric carcinoids and is characterized by a far more aggressive course. The optimal clinical approach to GCs remains to be elucidated, depending upon type, size, and number of carcinoids. While there is universal agreement about the surgical treatment of type III GCs, current options for type I and II include simple surveillance, endoscopic polypectomy, surgical excision associated with or without surgical antrectomy, or total gastrectomy. Moreover, the introduction of somatostatin analogues could represent another therapeutic option.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.